Fresh out of 6 Di­men­sion­s' in­cu­ba­tor, Curon launch­es with $150M and back­ing from Boyu, Temasek

The lat­est mega-round in the Chi­na biotech scene fea­tures some of the hottest VCs — and a pret­ty mys­te­ri­ous start­up.

Curon Bio­phar­ma­ceu­ti­cals has reaped $150 mil­lion in a Se­ries A round that pulled in 6 Di­men­sions Cap­i­tal, Boyu Cap­i­tal and Temasek.

The Shang­hai-based biotech was in­cu­bat­ed by 6 Di­men­sions, which not­ed in a press re­lease that it cur­rent­ly holds “mul­ti­ple” can­cer im­munother­a­py as­sets — to be ad­vanced in­to pre­clin­i­cal and clin­i­cal phas­es us­ing the new round of fund­ing. The mon­ey will al­so go to­ward ex­pand­ing the pipeline, though it’s un­clear ex­act­ly how.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.